EGFRmutantnon-smallcelllungcancer相关论文
TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimerti
Osimertinib(AZD9291)has been widely used for the treatment of EGFR mutant non-small cell lung cancer.However,resistance ......